Cost-Effectiveness of Fidaxomicin for Clostridium difficile Treatment

被引：2
|
作者：
Simon, Matthew S. [1 ,2 ]
机构：
[1] Weill Cornell Med Coll, Dept Med, New York, NY 10065 USA
[2] Weill Cornell Med Coll, Dept Publ Hlth, New York, NY 10065 USA
来源：
CLINICAL INFECTIOUS DISEASES | 2014年 / 58卷 / 04期
关键词：
VANCOMYCIN; INFECTION; CANCER;
D O I：
10.1093/cid/cit772
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Fidaxomicin in the treatment of Clostridium difficile infection in oncohematology patients
    Martin Rizo, Lara
    Malpartida Flores, Maria
    Fernandez Lison, Luis Carlos
    MEDICINA CLINICA, 2019, 153 (07): : 298 - 299
  • [42] Extended-pulsed fidaxomicin versus vancomycin in patients 60 years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
    Carlos Rubio-Terrés
    José María Aguado
    Benito Almirante
    Javier Cobo
    Santiago Grau
    Miguel Salavert
    Elena González Antona Sánchez
    Cristina López Gutiérrez
    Darío Rubio-Rodríguez
    European Journal of Clinical Microbiology & Infectious Diseases, 2019, 38 : 1105 - 1111
  • [43] COST-EFFECTIVENESS ANALYSIS OF MULTIPLE STRATEGIES FOR RECURRENT CLOSTRIDIUM DIFFICILE INFECTION
    Luo, Yuying
    Lucas, Aimee L.
    Grinspan, Ari
    GASTROENTEROLOGY, 2018, 154 (06) : S191 - S192
  • [44] COST-EFFECTIVENESS OF BEZLOTOXUMAB FOR THE PREVENTION OF RECURRENCE OF CLOSTRIDIUM DIFFICILE INFECTION IN PORTUGAL
    Silva, F.
    Lobo, I
    Pereira, R.
    Jiang, Y.
    Marcella, S.
    VALUE IN HEALTH, 2018, 21 : S226 - S226
  • [45] COST-EFFECTIVENESS OF STRATEGIES FOR THE MANAGEMENT OF SUSPECTED CLOSTRIDIUM DIFFICILE ASSOCIATED DIARRHEA
    CUCHURAL, GJ
    TALLY, FP
    CHANG, TW
    PAUKER, SG
    MEDICAL DECISION MAKING, 1983, 3 (03) : 356 - 356
  • [46] Experience With Fidaxomicin as First-Line Treatment for C. difficile Infection (CDI): Clinical Outcomes and Cost-Effectiveness
    Planche, Tim
    Whitney, Laura
    Ahmad, Attiq
    Nesnas, John
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2014, 109 : S678 - S678
  • [47] Effectiveness of early use of fidaxomicin in preventing recurrence of Clostridium difficile infection
    Goldenberg, S. D.
    Wigglesworth, N.
    Wade, P.
    Price, N. M.
    JOURNAL OF HOSPITAL INFECTION, 2019, 102 (03) : 352 - 353
  • [48] Advances in the treatment of Clostridium difficile with fidaxomicin: a narrow spectrum antibiotic
    Sears, Pamela
    Ichikawa, Yoshi
    Ruiz, Nancy
    Gorbach, Sherwood
    PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012, 2013, 1291 : 33 - 41
  • [49] Fidaxomicin: A novel macrocyclic antibiotic for the treatment of Clostridium difficile infection
    Crawford, Tonya
    Huesgen, Emily
    Danziger, Larry
    AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2012, 69 (11) : 933 - 943
  • [50] Extended-pulsed fidaxomicin versus vancomycin in patients 60years and older with Clostridium difficile infection: cost-effectiveness analysis in Spain
    Rubio-Terres, Carlos
    Maria Aguado, Jose
    Almirante, Benito
    Cobo, Javier
    Grau, Santiago
    Salavert, Miguel
    Antona Sanchez, Elena Gonzalez
    Lopez Gutierrez, Cristina
    Rubio-Rodriguez, Dario
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2019, 38 (06) : 1105 - 1111
12345